EP4217013A2 - Flüssigkeitsverbandsystem - Google Patents
FlüssigkeitsverbandsystemInfo
- Publication number
- EP4217013A2 EP4217013A2 EP21814855.9A EP21814855A EP4217013A2 EP 4217013 A2 EP4217013 A2 EP 4217013A2 EP 21814855 A EP21814855 A EP 21814855A EP 4217013 A2 EP4217013 A2 EP 4217013A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- liquid bandage
- composition
- active component
- pharmaceutical active
- bandage composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CQVWXNBVRLKXPE-UHFFFAOYSA-N 2-octyl cyanoacrylate Chemical compound CCCCCCC(C)OC(=O)C(=C)C#N CQVWXNBVRLKXPE-UHFFFAOYSA-N 0.000 title claims abstract description 106
- 239000000203 mixture Substances 0.000 claims abstract description 73
- 239000000463 material Substances 0.000 claims abstract description 36
- 238000001035 drying Methods 0.000 claims abstract description 9
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 3
- 206010052428 Wound Diseases 0.000 claims description 30
- 208000027418 Wounds and injury Diseases 0.000 claims description 30
- 239000004615 ingredient Substances 0.000 claims description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000004599 antimicrobial Substances 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 230000035876 healing Effects 0.000 claims description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 229940121375 antifungal agent Drugs 0.000 claims description 6
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 6
- 239000013521 mastic Substances 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 5
- 230000000845 anti-microbial effect Effects 0.000 claims description 5
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 claims description 5
- 239000003357 wound healing promoting agent Substances 0.000 claims description 5
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical group O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 4
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 4
- 239000006096 absorbing agent Substances 0.000 claims description 4
- 229940072056 alginate Drugs 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 4
- 210000000416 exudates and transudate Anatomy 0.000 claims description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 4
- 229960001774 octenidine Drugs 0.000 claims description 4
- 229960005323 phenoxyethanol Drugs 0.000 claims description 4
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims description 3
- 108010001478 Bacitracin Proteins 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 claims description 3
- -1 allyl amines Chemical class 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000003212 astringent agent Substances 0.000 claims description 3
- 229960003071 bacitracin Drugs 0.000 claims description 3
- 229930184125 bacitracin Natural products 0.000 claims description 3
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims description 3
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 3
- 239000003589 local anesthetic agent Substances 0.000 claims description 3
- 229960005015 local anesthetics Drugs 0.000 claims description 3
- 229960003128 mupirocin Drugs 0.000 claims description 3
- 229930187697 mupirocin Natural products 0.000 claims description 3
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims description 3
- 229920001220 nitrocellulos Polymers 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 claims description 3
- 229960002673 sulfacetamide Drugs 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- WWJFFVUVFNBJTN-UIBIZFFUSA-N (2S)-2-[[(2S,3S,4S)-2-amino-4-hydroxy-4-(5-hydroxypyridin-2-yl)-3-methylbutanoyl]amino]-2-[(2R,3S,4S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]acetic acid Chemical class C[C@@H]([C@H](N)C(=O)N[C@@H]([C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O)C(O)=O)[C@H](O)c1ccc(O)cn1 WWJFFVUVFNBJTN-UIBIZFFUSA-N 0.000 claims description 2
- NMRPBPVERJPACX-UHFFFAOYSA-N (3S)-octan-3-ol Natural products CCCCCC(O)CC NMRPBPVERJPACX-UHFFFAOYSA-N 0.000 claims description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 2
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 claims description 2
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 claims description 2
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 claims description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 2
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 2
- 108010020326 Caspofungin Proteins 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 2
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 claims description 2
- 241000208690 Hamamelis Species 0.000 claims description 2
- 241000264877 Hippospongia communis Species 0.000 claims description 2
- 244000147568 Laurus nobilis Species 0.000 claims description 2
- 235000017858 Laurus nobilis Nutrition 0.000 claims description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 2
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 claims description 2
- 229930193140 Neomycin Natural products 0.000 claims description 2
- 229930184499 Nikkomycin Natural products 0.000 claims description 2
- 239000010103 Podophyllin Substances 0.000 claims description 2
- 108010093965 Polymyxin B Proteins 0.000 claims description 2
- 241000241413 Propolis Species 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- 239000012675 alcoholic extract Substances 0.000 claims description 2
- 229940126575 aminoglycoside Drugs 0.000 claims description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 2
- 229960003942 amphotericin b Drugs 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 150000003851 azoles Chemical class 0.000 claims description 2
- 229960001716 benzalkonium Drugs 0.000 claims description 2
- 229960005274 benzocaine Drugs 0.000 claims description 2
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 claims description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 2
- 229960003328 benzoyl peroxide Drugs 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 claims description 2
- 229960003034 caspofungin Drugs 0.000 claims description 2
- 229960003749 ciclopirox Drugs 0.000 claims description 2
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims description 2
- 235000017803 cinnamon Nutrition 0.000 claims description 2
- 229960002227 clindamycin Drugs 0.000 claims description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 2
- 229960004884 fluconazole Drugs 0.000 claims description 2
- 229940124307 fluoroquinolone Drugs 0.000 claims description 2
- 229940094952 green tea extract Drugs 0.000 claims description 2
- 235000020688 green tea extract Nutrition 0.000 claims description 2
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical group COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 claims description 2
- 150000002460 imidazoles Chemical class 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004130 itraconazole Drugs 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 239000004922 lacquer Substances 0.000 claims description 2
- 229960004194 lidocaine Drugs 0.000 claims description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
- 229940041033 macrolides Drugs 0.000 claims description 2
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 claims description 2
- 229960004313 naftifine Drugs 0.000 claims description 2
- 229960004927 neomycin Drugs 0.000 claims description 2
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 claims description 2
- 229940033329 phytosphingosine Drugs 0.000 claims description 2
- 229920000024 polymyxin B Polymers 0.000 claims description 2
- 229960005266 polymyxin b Drugs 0.000 claims description 2
- 229960001807 prilocaine Drugs 0.000 claims description 2
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 2
- 229940069949 propolis Drugs 0.000 claims description 2
- 229910001923 silver oxide Inorganic materials 0.000 claims description 2
- 229960003600 silver sulfadiazine Drugs 0.000 claims description 2
- 229940080281 sodium chlorate Drugs 0.000 claims description 2
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical group 0.000 claims description 2
- 229960005349 sulfur Drugs 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 239000010677 tea tree oil Substances 0.000 claims description 2
- 229940111630 tea tree oil Drugs 0.000 claims description 2
- 229960002722 terbinafine Drugs 0.000 claims description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims description 2
- 229960002372 tetracaine Drugs 0.000 claims description 2
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 2
- 229940085784 viola tricolor extract Drugs 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- 229940068475 zinc citrate Drugs 0.000 claims description 2
- 239000011746 zinc citrate Substances 0.000 claims description 2
- 235000006076 zinc citrate Nutrition 0.000 claims description 2
- 150000003952 β-lactams Chemical class 0.000 claims description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 229940060184 oil ingredients Drugs 0.000 claims 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 claims 1
- 229940045136 urea Drugs 0.000 claims 1
- 239000000306 component Substances 0.000 description 16
- 230000000699 topical effect Effects 0.000 description 9
- 239000000654 additive Substances 0.000 description 6
- 230000001464 adherent effect Effects 0.000 description 6
- 230000000843 anti-fungal effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000036572 transepidermal water loss Effects 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 238000004078 waterproofing Methods 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010056951 Actinic cheilitis Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 238000011362 radionuclide therapy Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 201000011138 superficial basal cell carcinoma Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940024986 topical antifungal imidazole and triazole derivative Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0052—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0076—Sprayable compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Definitions
- the present invention relates in general to a fast drying solution or suspension leading to a film and in particular to a liquid bandage which can be used to protect and treat wounds.
- U.S. Patent No. 10,350,433 describes a layer structure for epidermal radionuclide therapy including a proximal adherent layer for applying the layer structure on a patient's skin surface to be treated, an adherent layer consisting of a skin cream and/or skin gel being excluded; a flexible, transparent carrier layer that from a patient's view is located in a distal direction on top of the adherent layer; and at least one radionuclide-containing emission layer located on the carrier.
- the adherent layer is formed on the skin surface prior to assembling the layer structure.
- the adherent layer is formed on the skin surface prior to assembling the layer.
- the adherent layer being formed from a structure of a synthetic film sprayable onto the skin, in particular a liquid bandage on the basis of polyurethanes, polyacrylates, especially poly(butyl methacrylate, methyl methacrylate); or 2- octyl cyanoacrylate.
- the present invention relates to a fast drying solution of a film forming composition for protection of wounds and prevention of contamination of the wounds.
- the fast drying film can be a liquid bandage which can be applied directly to the wound for covering the wound after the film dries.
- Example of wounds include paper cuts, cuticle cuts, minor wounds, scratches and abrasions.
- the liquid bandage can be formed of a liquid bandage composition including one or more film forming materials.
- the film forming materials can be selected to have a short drying time to allow expeditious application of the liquid bandage.
- the liquid bandage composition is a fast drying solution including one or more solvents and one or more film forming material.
- the liquid bandage can include one or more additives.
- the additive is a wound healing agent and/or an exudate absorber.
- the additives can also include antimicrobials, antiseptics, pain reducers, transepidermal water loss (TEWL) prevention materials and ion exchanging ingredients.
- a liquid bandage composition comprising a film forming material and a therapeutically-effective amount of at least one wound healing agent in which the liquid bandage when applied to a wound improves healing, beyond benefits provided without use of the liquid bandage.
- the liquid bandage composition can be applied to the skin for example with a brush or airless system.
- the liquid bandage composition can be applied as a spray.
- the liquid bandage composition can be applied to a minor wound with a brush.
- the liquid bandage composition can be applied as a spray onto a scratch or abrasion.
- the liquid bandage composition dries to form a liquid bandage.
- the liquid bandage can provide mechanical protection of the wound and isolation from external factors.
- the external factors can include dangerous factors such as for example debris contaminants and irritants.
- the applied liquid bandage can support the healing of the wounds in a shorter time with an acceptable quality of healing.
- the liquid bandage composition can be formed of a material to provide wound oxygenation.
- the liquid bandage composition can be formed of a material to provide water proofing.
- the liquid bandage can have a long lasting wearing time. For example, the liquid bandage can maintain adherence to skin up to one week or more.
- the present invention is also directed to methods to prepare a liquid bandage and methods to administer the liquid bandage to a human subject.
- a liquid bandage can comprise a liquid bandage composition.
- the liquid bandage composition can comprise one or more film forming materials.
- the liquid bandage composition can be formed of a fast drying solution including one or more solvents and one or more film forming materials.
- Suitable solvents for use in forming the liquid bandage composition include alcohol, ketones, ethers and ethyl acetate.
- Suitable film forming materials include plasticizers and polymers to form quick setting films.
- the film forming material can also include pyroxyline. In one embodiment, the proxyline is about 10 to about 12% nitrated.
- the film forming material can also include collodion, flexible collodion and the like.
- Suitable materials include United States Pharmacopeia (USP) collodion and United States Pharmacopeia (USP) flexible collodion.
- the film forming material can include cellulose and cellulose derivatives. Suitable materials include cellulose acetate phthalates with plasticizers and water insoluble cellulose derivatives. The film forming material can also include cyanoacrylate.
- the liquid bandage can be formed of a material to provide wound oxygenation.
- the liquid bandage can be formed of a material to provide water proofing.
- the material can be a film forming material that could be breathable to the skin.
- the liquid bandage composition can include a therapeutically-effective amount of at least one pharmaceutical component as an active component.
- the pharmaceutical active component can include one or more wound healing ingredients.
- An example wound healing ingredient is alginate.
- the pharmaceutical active component can include one or more exudate absorbers. Suitable compounds or materials for exudate absorbers can include, without limitation, cellulosic derivatives, chitosan, styptics and astringents. Example astringents, without limitation, include glycolic extracts, alcoholic extracts, green tea extract, and Hamamelis extract.
- the pharmaceutical active component can include one or more antibacterial or anti-microbial components. Preferably, the antimicrobial is soluble in the solvent used to form the liquid bandage composition.
- Example antimicrobials which can be used in the liquid bandage compositions include, without limitation, octenidine, phenoxyethanol, iodine, tea tree oil, and mastic oil.
- the antimicrobial can be (a cationic antimicrobial.
- Example cationic antimicrobials include benzalkonium and benzalkonium chloride.
- Suitable antimicrobials also include cinnamon zeylanicum oil, glycereth h-18 at 1-2% and ethylhexanol, honey comb extract and chios mastic oil or mastic extracts.
- the pharmaceutical active component can also include hydroxy-acetophenone, laurus nobilis leaves extract, PCA ethyl cocoyl alginate, phytosphingosine, propolis cera, silver oxide, sodium chlorate, viola tricolor extract, zinc citrate, octenidine, benzalkonium chloride and phenoxyethanol.
- the pharmaceutical active component can include antibiotics.
- Suitable antibiotics include beta-lactam, macrolides, tetracycline, fluoroquinolones, and aminoglycoside.
- the pharmaceutical active component can include an antifungal.
- Example antifungal ingredients which can be used in the present invention include azoles, amphotericin B, nikkomycins, imidazoles, triazoles, allyl amines, fluconazole, itraconazole, imidazole and triazole derivatives.
- the antifungal ingredient can include an allylamine such as for example naftifine and terbinafine.
- the antifungal ingredient can include an ethinocandin such as for example caspofungin.
- the antifungal ingredient can be used for treating candidiasis and tinea.
- the pharmaceutical active component can include an antiviral for topical use.
- the pharmaceutical active component can include an essential oil.
- the liquid bandage composition can include a therapeutically-effective amount of one or more topical antimicrobials.
- Suitable topical antimicrobials can be used to treat acne.
- Example topical antimicrobials include erythromycin, clindamycin, benzoyl peroxide, sulfa cetamide, sulfur, salicylic acid and azelaic acid.
- Topical antimicrobials can include Over the Counter medicines including for example, mupirocin 2%, neomycin, bacitracin and polymyxin B.
- the liquid bandage can include a therapeutically-effective amount of one or more topical compositions for treating skin infections and fungal infections, such as, for example, griseofulvine.
- the liquid bandage can include one or more topical compositions to treat nail fungus, such as for example a nail lacquer of ciclopirox.
- the liquid bandage can include a therapeutically-effective amount of sulfonamides for topical use.
- the liquid bandage can include one or more ingredients for treating bums. Suitable ingredients can include silver sulfadiazine or matenide.
- the liquid bandage can include a therapeutically-effective amount of one or more ingredients for treating acne.
- the liquid bandage can include sulfacetamide or metronidazole.
- the liquid bandage can include ingredients for treating cutaneous infections.
- the liquid bandage can include a therapeutically-effective amount of one or more ingredients of mupirocin 2%, polymixin, bacitracin and fucidine
- the liquid bandage can include a therapeutically-effective amount of one or more ingredients for treating actinic keratoses, actinic cheilitis and superficial basal cell carcinomas.
- the liquid bandage can include flurouracil (5-FU ) or masopocol.
- the liquid bandage can include a therapeutically-effective amount of one or more ingredients for treating vitiligo.
- the liquid bandage includes tacrolimus for topical use with an ultra violet filter.
- the liquid bandage can include a therapeutically-effective amount of one or more ingredients for treating anti-black spots of the skin.
- the liquid bandage can include a therapeutically-effective amount of one or more ingredients for treating psoriasis.
- the ingredients can be provide via an aerosol.
- the liquid bandage can include a therapeutically-effective amount of one or more ingredients for treating warts. Suitable ingredients include salicylic acid, urea and podophyllum resin. In some embodiments, the liquid bandage can include propylene glycol , N- methyl-2-pyrrolidone or butyl glycol
- the pharmaceutical active component can include one or more pain reducer or local anesthetics.
- Example local anesthetics which can be used in the liquid bandage composition, without limitation, include lidocaine, benzocaine, prilocaine and tetracaine.
- the pharmaceutical active component according to the present invention can include pharmaceutically acceptable forms thereof, including isomers such as diastereomers and enantiomers, salts, solvates, and polymorphs, as well as racemic mixtures.
- the liquid bandage composition can comprise one or more additives to provide desired properties of a liquid bandage.
- the additives can include, without limitation, transepidermal water loss (TEWL) prevention materials and ion exchanging ingredients.
- TEWL transepidermal water loss
- the liquid bandage composition can comprise from about 0.1% to about 80% by weight or by volume of the film forming material, for example, 1.0- 80%, 5-75%, 10-60%, 20-40%, 25- 40%, or 30-40% by weight or by volume.
- the liquid bandage composition can comprise from about 0.1% to about 80% by weight or by volume of the solvent, for example, 1.0- 80%, 5-75%, 10-60%, 20-40%, 25-40%, or 30- 40% by weight or by volume.
- the liquid bandage composition can comprise from about 0.1% to about 45% by weight or by volume of the pharmaceutical or otherwise active agent, for example, 0.1-1.0%, 0.1-0.9%, 0.1-0.8%, 0.1-0.7%, 0.1-0.6%, 0.1-0.5%, 0.1-0.3%, 0.1-0.2%, l%-45%, 5%-40%, 10-35%, 10- 30%, 15-30.%, 20-30% or 25-30% by weight or by volume.
- the pharmaceutical or otherwise active agent is a wound healing agent which is present in an amount of 1 to 40 %, 1 to 30%, 5-40%, 10-35%, 10-30%, 15-30.%, 20-30% or 25-30% by weight or by volume.
- the composition can comprise from about 0.1% to about 10% by weight or by volume of the additive, for example, 0.1-1.0%, 0.1-0.9%, 0.1-0.8%, 0.1-0.7%, 0.1-0.6%, 0.1-0.5%, 0.1- 0.3%, 0.1-0.2%, 1-5%, 2-5%, 2-6%, 3-8%, 4.0-9%, 5-8%, 6-9 %,5-10%, 7-10%, or 9-10%, by weight or by volume.
- the composition comprises a film forming material present in an amount of about 1% to about 50% weight percent of the composition, a solvent present in an amount of about 1% to about 30% weight percent of the composition and a wound healing agent present in an amount of about 1% to about 20% weight percent of the composition.
- the liquid bandage composition can be formulated by mixing two or more of the ingredients at room temperature. In one embodiment, all ingredients of the liquid bandage composition can be mixed at room temperature. Alternatively, the ingredients during mixing could be heated up to 50°C. In one embodiment, the solids content of the liquid bandage is 97%.
- the liquid bandage according to the present invention can be administered to or applied to a human or other animal subject.
- the liquid bandage may be suitable for administration or application to skin of a human subject.
- the liquid bandage is for protection of wounds and prevention of contamination of the wounds.
- the liquid bandage composition can be applied directly to the wound for covering the wound.
- the liquid bandage composition dries after application to the skin to form a film covering the wound.
- the liquid bandage composition can be applied by brushing the liquid bandage composition over the wound.
- the liquid bandage composition can be applied with an airless system, such as a for example a pump bottle.
- the liquid bandage composition can be applied as a spray of the liquid bandage composition.
- the present invention provides a method of wound care and improving healing of a wound in a subject comprising administering a therapeutically effective amount of a liquid bandage composition comprising a therapeutically-effective amount of at least one film forming material and at least one pharmaceutical therapeutic active component.
- the present invention further provides a liquid bandage comprising a therapeutically- effective of at least one pharmaceutical active component, wherein the at least one pharmaceutical active component improves healing of a wound beyond benefits provided by not applying the liquid bandage to the wound.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082031P | 2020-09-23 | 2020-09-23 | |
| PCT/IB2021/000655 WO2022064276A2 (en) | 2020-09-23 | 2021-09-23 | Liquid bandage system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4217013A2 true EP4217013A2 (de) | 2023-08-02 |
Family
ID=78770816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21814855.9A Pending EP4217013A2 (de) | 2020-09-23 | 2021-09-23 | Flüssigkeitsverbandsystem |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4217013A2 (de) |
| WO (1) | WO2022064276A2 (de) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011050848B4 (de) | 2011-06-06 | 2015-10-01 | ITM Isotopen Technologien München AG | Schichtaufbau zur epidermalen Radionuklidtherapie |
| CN108135745B (zh) * | 2016-06-29 | 2021-05-14 | 艾威药业(珠海)有限公司 | 用于伤口处理的有效新型快速沉积薄膜形成组合物 |
-
2021
- 2021-09-23 EP EP21814855.9A patent/EP4217013A2/de active Pending
- 2021-09-23 WO PCT/IB2021/000655 patent/WO2022064276A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022064276A2 (en) | 2022-03-31 |
| WO2022064276A3 (en) | 2022-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0247142B1 (de) | Filmbildende arzneimittelträger zur verabreichung von arzneimitteln an nägeln; verfahren zur verwendung | |
| EP3106157B1 (de) | Antiseptische zusammensetzungen mit silberionen und menthol und verwendungen davon | |
| US20030180347A1 (en) | Patch for the delivery of topical agents | |
| ES2611351T3 (es) | Formulación para tratamiento tópico de heridas | |
| KR20010012464A (ko) | 화상 치료 및 감염 방지를 위한 국소 분무 | |
| JP5179879B2 (ja) | 組成物 | |
| DE2443180A1 (de) | Verbandsmaterial fuer wunden und dessen verwendung | |
| EP2395973B1 (de) | In situ haft-gelbildende zubereitungen, insbesondere zur topischen anwendung auf befeuchtete haut/schleimhaut | |
| US6555125B2 (en) | Lesion and ulcer medication | |
| DE10361022A1 (de) | Topische Zubereitungen enthaltend Dimethylsulfoxid und Dexpanthenol | |
| PL179918B1 (pl) | Srodek farmaceutyczny do leczenia schorzen skóry i sposób wytwarzania tego srodka farmaceutycznego PL PL PL PL PL PL PL | |
| CN1814279A (zh) | 重组人碱性成纤维细胞生长因子凝胶剂及其制备方法 | |
| RU2012149863A (ru) | Полисахарид семени тамаринда для применения в лечении микробных инфекций | |
| WO2022064276A2 (en) | Liquid bandage system | |
| KR20110027434A (ko) | 약물의 서방출이 가능한 발수필름 형성용 조성물 | |
| JP2000095681A (ja) | 創傷治癒のための局所用薬剤組成物類 | |
| EP3210619A2 (de) | Topische formulierung zur behandlung von haut- oder schleimhautinfektionen, herstellungsverfahren und verwendungen davon | |
| CN110898038A (zh) | 一种鲨鱼肽凝胶涂膜剂及其制备方法 | |
| Babickaite et al. | Therapeutic activity of chlorhexidine-poloxamer antiseptic gel on wound healing in rats: a preclinical study | |
| US10912753B1 (en) | Topical skin care composition | |
| KR101593208B1 (ko) | 에어로졸 스프레이형 하이드로겔 화상치료제 | |
| ES2652313B1 (es) | Procedimiento de preparación de un producto a base de las hojas de la planta Sedum telephium para el tratamiento de las uñas infectadas de onicomicosis | |
| EP3348307A1 (de) | Zusammensetzung mit carnitin, natriumcholat, natriumacetat und gegebenenfalls silber zur verwendung in der behandlung von psoriasis, vitiligo und rosazea | |
| AU2018309734A1 (en) | Alkyl dimethyl organosilane quaternaries in persistent systems and methods | |
| CN107998071B (zh) | 一种提高苯妥英银稳定性的方法及苯妥英银外用制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230421 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) |